Corbus says new data shows its monoclonal antibody demonstrates robust pre-clinical anti-tumor activity alone and in combination with anti-PD-1 therapy.
The UK company makes two announcements for its Jemperli (dostarlimab) treatment, after it successfully cleared a Phase II trial and is set to enter a new Phase III trial in combination with cobolimab.
Regeneron and Sanofi’s Libtayo is granted marketing authorization by the European Commission for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma.
